StockNews.com began coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Rating) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
CASI has been the subject of several other reports. HC Wainwright lowered their price target on CASI Pharmaceuticals from $40.00 to $30.00 in a research report on Friday, May 13th. BTIG Research lifted their target price on CASI Pharmaceuticals from $4.00 to $21.00 and gave the company a buy rating in a report on Friday, June 3rd.
CASI Pharmaceuticals Price Performance
Shares of CASI Pharmaceuticals stock opened at $2.50 on Tuesday. The business has a 50 day simple moving average of $2.84 and a two-hundred day simple moving average of $5.33. CASI Pharmaceuticals has a 12 month low of $2.24 and a 12 month high of $17.40. The stock has a market capitalization of $34.02 million, a P/E ratio of -1.14 and a beta of 0.64.
Institutional Trading of CASI Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of CASI. Citigroup Inc. acquired a new stake in shares of CASI Pharmaceuticals during the first quarter worth about $59,000. Bailard Inc. increased its position in shares of CASI Pharmaceuticals by 25.6% during the second quarter. Bailard Inc. now owns 31,530 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 6,430 shares in the last quarter. Virtu Financial LLC increased its position in CASI Pharmaceuticals by 39.6% in the 1st quarter. Virtu Financial LLC now owns 112,777 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 31,971 shares during the period. Finally, Wellington Shields & Co. LLC increased its position in CASI Pharmaceuticals by 27.3% in the 1st quarter. Wellington Shields & Co. LLC now owns 1,453,190 shares of the biotechnology company’s stock valued at $1,177,000 after acquiring an additional 312,000 shares during the period. 39.51% of the stock is currently owned by institutional investors and hedge funds.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
- Get a free copy of the StockNews.com research report on CASI Pharmaceuticals (CASI)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.